RxDoctor Payments Data

Devang Desai, MD

Cardiovascular Disease · Reno, NVNPI 1013110998

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (53.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Johnson & Johnson at 56.3% of the total. Reporting peaked in 2022 at $54,190 and has fallen 69.1% since, to $16,765 in 2025. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$206,268in general payments, 2019–2025

Across 875 payments — averaging $235.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$116K
  • Edwards Lifesciences$69K
  • Medtronic$8K
  • Boston Scientific$3K
  • Abbott$2K
  • Angiodynamics, Inc.$2K
  • plus $6K from 41 others

What the payments were for

  • Consulting fees$52,70026%
  • Speaking & faculty fees$110,86054%
  • Travel & lodging$16,8708%
  • Food & beverage$23,93512%
  • Other$1,9021%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$206,268 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada

Medicare billing

Part B allowed, 2024
$535,802
Medicare patients
1,030
Services billed
3,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$307,495
XareltoRivaroxaban150$194,698
EntrestoSacubitril/Valsartan62$79,607
Repatha SureclickEvolocumab49$65,190
BrilintaTicagrelor44$45,960
JardianceEmpagliflozin19$30,753
Praluent PenAlirocumab21$17,577
NexlizetBempedoic Acid/Ezetimibe19$14,007
Rosuvastatin Calcium421$11,562
Atorvastatin Calcium507$8,913
Metoprolol Succinate522$7,802
Amlodipine Besylate518$5,509
Diltiazem 12hr ErDiltiazem Hcl11$3,534
Dofetilide11$3,226
Losartan Potassium238$3,131

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$319$307,495247 claims
Johnson & JohnsonXarelto$116,101$194,698150 claims
NovartisEntresto$1,245$79,60762 claims
AstraZenecaBrilinta$183$45,96044 claims
Boehringer IngelheimJardiance, Pradaxa$332$33,46231 claims
Esperion Therapeutics, Inc.Nexlizet$121$14,00719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 165 cardiovascular disease providers in Nevada.

Other cardiovascular disease in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →